

AstraZeneca PLC
Registered in England No. 2723534
1 Francis Crick Avenue,
Cambridge Biomedical Campus,
Cambridge CB2 0AA
Tel +44 (0)20 3749 5000
www.astrazeneca.com



Dear Shareholder

On behalf of the Board of AstraZeneca PLC (the Company), I am pleased to confirm that the Annual Report and Form 20-F Information 2023 (the Annual Report) has now been published, as well as the Notice of Annual General Meeting 2024 and Shareholders' Circular (the Notice of AGM).

What you should have received

If you have previously requested paper copies of these documents, you will find paper copies enclosed. If you have previously elected to receive these documents via the AstraZeneca website, you can now access the Annual Report at www.astrazeneca.com and the Notice of AGM at www.astrazeneca.com/noticeofmeeting2024.

Everyone who receives a hard copy of this document will also find enclosed a proxy card or voting card.

Communicating with you

I would urge shareholders who currently receive communications from the Company in hard copy to consider opting to receive all future information from the Company in electronic format. There are clear environmental benefits and cost savings arising from reduced paper usage, printing and distribution if you do so.

You can elect to receive shareholder communications in electronic format by registering your details at www.shareview.co.uk and electing for e-communications. Whenever shareholder communications are published, we will send you an email with a link to the information on the AstraZeneca website.

Yours faithfully

A handwritten signature in black ink that reads "Michel Demaré".

Michel Demaré
Chair of the Board
8 March 2024